Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Mirikizumab Prefilled Syringe vs Autoinjector in Healthy Participants
NCT04607733Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2020
- Primary completion
- May 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of mirikizumab in ulcerative colitis (UC) and Crohn's disease (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Maximum Plasma Concentration, Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity and 1 more. Started Nov 2020; status: completed.
02
Drugs
mirikizumab
03
Conditions
ulcerative colitis (UC)Crohn's disease
Beyond the preview
Go deeper on NCT04607733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04607733.